Results 51 to 60 of about 2,530 (165)
American Journal of Ophthalmology Case Reports, 2022 Purpose: To report on a case of successful treatment of intraocular inflammation (IOI) secondary to brolucizumab intravitreal injection that responded to a single sub-Tenon injection of triamcinolone.
Shree K. Kurup +3 more
doaj +1 more source
Novel Resolution of Multilayered Pigment Epithelial Detachment Lamellae Following Brolucizumab Treatment-A Case Report. [PDF]
Case Rep Ophthalmol MedPurpose: The aim of this study is to report a unique case where brolucizumab administration resolved multilayered pigment epithelial detachment (MLPED) lamellae. Observations: An 80‐year‐old gentleman with polypoidal choroidal vasculopathy developed MLPED from long‐term ranibizumab treatment.
Nair U, Nair IJ, Sheth JU, Soman M.
europepmc +2 more sources
Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration. [PDF]
, 2023 Nowadays; intravitreal anti-vascular endothelial growth factor (VEGF) drugs are considered the first-line therapeutic strategy for treating macular exudative diseases; including wet age-related macular degeneration (w-AMD) and diabetic macular edema (DME)
Ferro Desideri, Lorenzo +3 more
core +1 more source
The prechoroidal cleft in neovascular age‐related macular degeneration
Acta Ophthalmologica, EarlyView.Abstract The prechoroidal cleft is a lenticular, hypo‐reflective space on optical coherence tomography imaging, located between a band of fibrovascular material underneath the retinal pigment epithelium (RPE) and Bruch's membrane. It occurs in 8%–22% of neovascular age‐related macular degeneration (nAMD) eyes, most often with macular neovascularization
Niels J. Brouwer +3 more
wiley +1 more source
Medication-induced Uveitis: An Update [PDF]
, 2021 Drug-induced uveitis is an uncommon but important cause of ocular inflammation. Uveitis can be seen in association with various systemic, topical, and intraocular medications. In this article, we review common medications associated with uveitis.
Emami-Naeini, Parisa +2 more
core +2 more sources
Clinical &Experimental Ophthalmology, Volume 53, Issue 9, Page 1156-1167, December 2025.ABSTRACT Background We aimed to describe 1‐year outcomes of eyes switched to faricimab from first‐generation vascular endothelial growth factor (VEGF) inhibitors for neovascular age‐related macular degeneration (nAMD) in routine care. Methods Multicentre, observational study of 383 eyes tracked in the Fight Retinal Blindness!
Adrian Hunt +9 more
wiley +1 more source
Association of Polyp Regression after Loading Phase with 12-Month Outcomes of Eyes with Polypoidal Choroidal Vasculopathy [PDF]
Purpose: We compared 12-month outcomes of eyes with polypoidal choroidal vasculopathy (PCV) with or without complete regression of polyps observed one month after three monthly intravitreal administrations (loading phase) of aflibercept (2.0 mg/0.05 mL ...
00535619 +37 more
core +1 more source
Clinical Case Reports, Volume 13, Issue 11, November 2025.ABSTRACT In eyes with a scleral‐fixated IOL, intravitreal triamcinolone may migrate into the anterior chamber, resulting in early‐onset elevation of IOP, even at small volumes. Prompt slit lamp and gonioscopic evaluation is recommended for patients with prior vitrectomy or posterior capsule defects to ensure timely detection and treatment.
Yuki Takagi +2 more
wiley +1 more source
Ophthalmology and Therapy, 2023 Introduction Intraocular inflammation (IOI)-related adverse events (AEs) that may result in severe vision loss have been associated with the anti-vascular endothelial growth factor brolucizumab.
Ryan Zubricky +8 more
doaj +1 more source